Table 4 The most common toxicities in patients with BRAF V600E-mutated mCRC in standard therapy group (treated with cytotoxic doublets with or without bevacizumab) and intensive therapy group (treated with modified FOLFOXIRI regimen)
Toxicity (NCI-CTC grade) | Standard therapy group (n = 50) | Intensive therapy group (n = 6) | ||||||
|---|---|---|---|---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
Thrombocytopenia | 18 (36.0) | 1 (2.0) | 0 (0) | 0 (0) | 0 (0) | 1 (16.7) | 0 (0) | 0 (0) |
Anemia | 15 (30.0) | 14 (28.0) | 3 (6.0) | 0 (0) | 0 (0) | 2 (33.3) | 0 (0) | 0 (0) |
Nausea | 15 (30.0) | 9 (18.0) | 0 (0) | 0 (0) | 2 (33.3) | 1 (16.7) | 0 (0) | 0 (0) |
Peripheral neurotoxicity | 13 (26.0) | 14 (28.0) | 0 (0) | 0 (0) | 2 (33.3) | 1 (16.7) | 0 (0) | 0 (0) |
Astenia | 11 (22.0) | 11 (22.0) | 1 (2.0) | 0 (0) | 0 (0) | 1 (16.7) | 0 (0) | 0 (0) |
Vomiting | 10 (20.0) | 5 (10.0) | 0 (0) | 0 (0) | 2 (33.3) | 0 (0) | 0 (0) | 0 (0) |
Diarrhea | 10 (20.0) | 4 (8.0) | 0 (0) | 0 (0) | 2 (33.3) | 1 (16.7) | 0 (0) | 0 (0) |
Neutropenia | 10 (20.0) | 13 (26.0) | 15 (30.0) | 6 (12.0) | 0 (0) | 2 (33.3) | 1 (16.7) | 1 (16.7) |
Stomatitis | 9 (18.0) | 5 (10.0) | 0 (0) | 0 (0) | 1 (16.7) | 0 (0) | 0 (0) | 0 (0) |
Hypertension | 3 (6.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Hemorrhage | 3 (6.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |